Nothing Special   »   [go: up one dir, main page]

EA201100668A1 - Способы продуцирования антител из плазматических клеток - Google Patents

Способы продуцирования антител из плазматических клеток

Info

Publication number
EA201100668A1
EA201100668A1 EA201100668A EA201100668A EA201100668A1 EA 201100668 A1 EA201100668 A1 EA 201100668A1 EA 201100668 A EA201100668 A EA 201100668A EA 201100668 A EA201100668 A EA 201100668A EA 201100668 A1 EA201100668 A1 EA 201100668A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
antibodies
producing antibodies
relates
antibody fragments
Prior art date
Application number
EA201100668A
Other languages
English (en)
Other versions
EA024586B1 (ru
Inventor
Антонио Ланзавечи
Дэвид Джарроссэй
Original Assignee
Институт Фо Ресёч Ин Биомедицине
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41796120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201100668(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0819376A external-priority patent/GB0819376D0/en
Priority claimed from US12/509,731 external-priority patent/US9340603B2/en
Application filed by Институт Фо Ресёч Ин Биомедицине filed Critical Институт Фо Ресёч Ин Биомедицине
Publication of EA201100668A1 publication Critical patent/EA201100668A1/ru
Publication of EA024586B1 publication Critical patent/EA024586B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к способам продуцирования антител, включая моноклональные антитела, включающим культивацию ограниченного числа плазматических клеток. Оно также относится к способам идентификации антител путем проведения анализов антител, продуцируемых культивируемыми плазматическими клетками, для определения их функции, специфичности связывания, специфичности к эпитопам и/или их способности нейтрализовать токсин или патоген. Изобретение также относится к антителам и фрагментам антител, продуцируемым с помощью способов по изобретению, а также к способам использования антител и фрагментов антител.
EA201100668A 2008-10-22 2009-10-22 Способы продуцирования антител из плазматических клеток EA024586B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0819376A GB0819376D0 (en) 2008-10-22 2008-10-22 Method for culturing human plasma cells
US18158209P 2009-05-27 2009-05-27
US12/509,731 US9340603B2 (en) 2008-07-25 2009-07-27 Neutralizing anti-influenza A virus antibodies and uses thereof
PCT/IB2009/006616 WO2010010466A2 (en) 2008-07-25 2009-07-27 Neutralizing anti-influenza a virus antibodies and uses thereof
PCT/IB2009/007375 WO2010046775A2 (en) 2008-10-22 2009-10-22 Methods for producing antibodies from plasma cells

Publications (2)

Publication Number Publication Date
EA201100668A1 true EA201100668A1 (ru) 2012-06-29
EA024586B1 EA024586B1 (ru) 2016-10-31

Family

ID=41796120

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100668A EA024586B1 (ru) 2008-10-22 2009-10-22 Способы продуцирования антител из плазматических клеток

Country Status (19)

Country Link
US (1) US9347043B2 (ru)
EP (2) EP2350128B1 (ru)
JP (1) JP5837820B2 (ru)
KR (1) KR101606608B1 (ru)
CN (1) CN102282170B (ru)
AU (1) AU2009306010B2 (ru)
BR (1) BRPI0914092B1 (ru)
CA (1) CA2740138C (ru)
CL (1) CL2011000797A1 (ru)
DK (1) DK2350128T3 (ru)
EA (1) EA024586B1 (ru)
ES (1) ES2525346T3 (ru)
HK (1) HK1164899A1 (ru)
IL (1) IL212121A (ru)
MX (1) MX2011003855A (ru)
NZ (1) NZ592036A (ru)
PL (1) PL2350128T3 (ru)
WO (1) WO2010046775A2 (ru)
ZA (1) ZA201102387B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110212106A1 (en) 2010-01-20 2011-09-01 Institute For Research In Bioscience Hiv-1 neutralizing antibodies and uses thereof
PL2400298T3 (pl) * 2010-05-28 2014-01-31 Hoffmann La Roche Sposób hodowania pojedynczych komórek b oraz wytwarzania swoistych przeciwciał
US20130115606A1 (en) 2010-07-07 2013-05-09 The University Of British Columbia System and method for microfluidic cell culture
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
US9487583B2 (en) * 2011-03-30 2016-11-08 National University Corporation University Of Toyama Method for selecting plasma cells or plasmablasts, method for producing target antigen specific antibodies, and novel monoclonal antibodies
ES2732552T3 (es) 2011-07-18 2019-11-25 Inst Res Biomedicine Anticuerpos neutralizantes del virus de la influenza A y usos de los mismos
EA030319B1 (ru) 2012-03-20 2018-07-31 Хумабс Биомед Са Антитела, нейтрализующие rsv, mpv и pvm, и их применения
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
SI3220947T1 (sl) 2014-11-18 2021-02-26 Humabs Biomed S.A. Protitelesa, ki močno nevtralizirajo virus stekline in druge lisaviruse in njihove uporabe
US20180179274A1 (en) 2015-06-26 2018-06-28 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN105950552A (zh) * 2016-05-26 2016-09-21 宁波艾科生物科技有限公司 一种分泌抗原特异性抗体浆细胞的分离方法
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
AU2018253918A1 (en) 2017-04-19 2019-10-31 Institute For Research In Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
JP6622825B2 (ja) * 2018-01-25 2019-12-18 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
FI3898668T3 (fi) 2018-12-19 2023-11-28 Humabs Biomed Sa B-hepatiittivirusta neutraloivia vasta-aineita ja niiden käyttöjä
CA3132521A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2020221451A1 (en) 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies binding to plasmodium circumsporozoite protein and uses thereof
WO2020221450A1 (en) 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection
EP3757127A1 (en) 2019-06-28 2020-12-30 Institute for Research in Biomedicine Deimmunized antibodies binding to alpha-4 integrin and uses thereof
JP2022545920A (ja) 2019-08-29 2022-11-01 ヴィア・バイオテクノロジー・インコーポレイテッド Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
CN115052630A (zh) 2019-08-29 2022-09-13 维尔生物科技有限公司 用于治疗甲型流感感染的组合物和方法
JP2020048568A (ja) * 2019-11-22 2020-04-02 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
IL299201A (en) 2020-06-24 2023-02-01 Vir Biotechnology Inc Transgenic hepatitis B virus neutralizing antibodies and their uses
WO2022125517A1 (en) 2020-12-08 2022-06-16 Vir Biotechnology, Inc. Antibodies and methods for treatment of influenza a infection
WO2022122704A1 (en) 2020-12-08 2022-06-16 Humabs Biomed Sa Antibodies binding to f-protein of metapneumovirus and uses thereof
WO2022161598A1 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
WO2022161597A1 (en) 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies
WO2022164805A1 (en) 2021-01-26 2022-08-04 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
WO2022162009A1 (en) 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies
WO2022162012A2 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
WO2023036774A1 (en) 2021-09-07 2023-03-16 Institute For Research In Biomedicine Antibodies binding to tetanus toxin and uses thereof
CN114350606A (zh) * 2022-01-05 2022-04-15 上海药明生物医药有限公司 一种富集大鼠浆细胞及建立浆细胞杂交瘤的方法
AR129399A1 (es) 2022-05-23 2024-08-21 Vir Biotechnology Inc Anticuerpos diseñados neutralizantes del virus de la hepatitis b y usos de los mismos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US7368256B2 (en) * 2001-08-10 2008-05-06 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Antibodies against Stachybotrys chartarum and methods for their use
RS20050834A (en) * 2002-08-19 2007-12-31 Abgenix Inc., Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US7288253B2 (en) * 2003-08-08 2007-10-30 Amgen Fremont, Inc. Antibodies directed to parathyroid hormone (PTH) and uses thereof
CA2652452C (en) 2006-05-15 2018-07-31 Sea Lane Biotechnologies, Llc Neutralizing antibodies to influenza viruses
EP2059532B1 (en) 2006-09-07 2012-12-26 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
CA2668800A1 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
EP2125886A2 (en) 2007-03-13 2009-12-02 Humabs LLC Antibodies against h5n1 strains of influenza a virus
US8524656B2 (en) * 2008-07-08 2013-09-03 Jacques Galipeau GM-CSF and truncated CCL2 conjugates and methods and uses thereof

Also Published As

Publication number Publication date
KR101606608B1 (ko) 2016-03-25
IL212121A0 (en) 2011-06-30
US9347043B2 (en) 2016-05-24
EP2350128A2 (en) 2011-08-03
MX2011003855A (es) 2011-12-16
DK2350128T3 (da) 2014-12-01
AU2009306010B2 (en) 2015-12-24
NZ592036A (en) 2012-12-21
CL2011000797A1 (es) 2012-03-16
CN102282170A (zh) 2011-12-14
ZA201102387B (en) 2012-09-26
JP5837820B2 (ja) 2015-12-24
BRPI0914092A2 (pt) 2015-10-27
PL2350128T3 (pl) 2015-03-31
ES2525346T3 (es) 2014-12-22
US20100145031A1 (en) 2010-06-10
CN102282170B (zh) 2015-04-08
AU2009306010A1 (en) 2010-04-29
CA2740138C (en) 2017-01-10
WO2010046775A3 (en) 2010-06-17
EP2350128B1 (en) 2014-10-01
CA2740138A1 (en) 2010-04-29
KR20110073506A (ko) 2011-06-29
WO2010046775A2 (en) 2010-04-29
EP2848630A1 (en) 2015-03-18
IL212121A (en) 2016-03-31
EA024586B1 (ru) 2016-10-31
HK1164899A1 (en) 2012-09-28
BRPI0914092B1 (pt) 2021-08-31
JP2012506251A (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
EA201100668A1 (ru) Способы продуцирования антител из плазматических клеток
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
MX2018013008A (es) Anticuerpos st-2 humanos solubles y ensayos.
IN2014MN00873A (ru)
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
MX2011000767A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
EA201170205A1 (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
CR9562A (es) Anticuerpos anti-cd40 humanizados y sus metodos de uso
EA200800812A1 (ru) Композиции антитела против cd3
MX353144B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
MX2014000749A (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
MX2014001799A (es) Anticuerpos sin fc qie comprenden dos fragmentos fab y metodos de uso.
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
CO6781489A2 (es) Proteínas de unión al tnf-α
TN2014000120A1 (en) Cd27l antigen binding proteins
BR112013021350A2 (pt) anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes
TN2014000107A1 (en) Anti-aplhabetatcr antibody
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
NZ611600A (en) Means and methods for producing high affinity antibodies
NZ616382A (en) Antibodies specific to cadherin-17
EA201491724A1 (ru) Антитела, нейтрализующие rsv, mpv и pvm, и их применения
PE20220004A1 (es) Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh
TR201819828T4 (tr) Anti-fosfolipaz d4 antikoru.
RU2015107740A (ru) Способ измерения, реагент для измерения и набор для измерения pivka-ii

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ RU